"In a market hyped with unsubstantiated cannabis products claims, we made it our mission to bring a scientific and innovative approach to wellness you can rely on. From plant research to clinical studies on novel cannabinoid formulations, we deliver validated, evidence-based OTC products".
NES (n. definition-miracle)
Neswell methodology combines the traditional holistic approach with state-of-the-art research. Our scientists believe in taming the unique compounds of Cannabis by standardizing this NES for the world of wellness. With true validation to back research, Neswell Group is developing natural, safe and clinically tested products to combat the global unmet need.
NI (n. definition-Neswell Inside)
Neswell therapeutics designed for local effect, utilize pharma technologies to create a wellness standard that verifies researched and clinically validated cannabis products. We collect data points from seed to product to create consistent, plant-based OTC solutions for a variety of indication reliefs (Anti-inflammation, Analgesic, etc.). Our tailor-made formulations are trademarked with NI standard, containing broad-spectrum Cannabis Sativa L. / Hemp extract and delivered by novel administration systems for optimal bio-availability.
WHAT MAKES UP NI?
PLANT TO PRODUCT
Perfecting the Building Blocks of Plant-Based Therapeutics
NES (n. definition-miracle)
Neswell's research operation runs in our independent labs in Tel Aviv and via collaborations with advance labs in the Hebrew University, Hadassah Ein Karem Hospital and research labs in the US.
RON SHIMONI, MBA
Co-Founder & CEO
A multidisciplinary business leader with vast experience and knowledge in creating and managing successful ventures in the global arena. Ron's background varies in marketing, tech, and retail businesses, and has an MBA in Strategic Management and Innovation.
PROF. ODED SHOSEYOV
Co-Founder & CSO
A leading researcher and a faculty member in the Hebrew University. Expert in plant molecular biology and Nano-biotechnology. A managing member in the ‘Israeli Cannabinoid Center' and co-authored almost 50 patents.
Co-Founder & COO
An operational expert in the cannabis industry, with deep knowledge in Israeli regulation. Expert in the licensing process of medical cannabis operations.
Has experience in the cultivation and production
A leading researcher with vast experience in drug development and delivery. Holding a Ph.D in biotechnology from TAU, Ronit brings 7 years of pharmaceutical experience to the field of research, innovation and product management.
Head of Plant research
M.Sc. in Plant Science from the Hebrew University and has led a variety of R&D projects.
Jonathan has extensively advised as a scientific consultant for cannabis companies.
PROF. OFRA BENNY, Ph.D
Expert in Formulations and drug Delivery methods
A faculty member in the Hebrew University, with PH.D from Harvard Medical school. Has more than ten years of experience in biological/medical research and nanotechnology.
DR. DUDU POLAK, MD
Expert in Immunology and Anti-Inflammatory Research
A faculty member in the Hebrew University and a leading researcher in the Hadassah Ein Kareem medical center. Dudu is recognized for his massive track record of successful projects.
DANA YARDEN, MD
Clinical & Medical Advisor
Dr. Yarden brings with her more than 10 years of experience in medical R&D, biotechnology, business development and clinical research. Formerly Dana served as the Clinical and BD Affairs Officer at Collplant and BioLineRx.
Business Development & Financial Investment Professional
An innovative creator of cross-country and continent investments opportunities. Eran has more than 25 years of experience in establishing and managing investments.
DR. NOA LEIBOVITCH, Ph.D
Scientific and strategic consultant
Dr. Leibovitch has over two decades of experience in the pharma industry where she held various positions at Teva Pharmaceutical Industries Global R&D. In her last position she served as Senior VP, Global Head, Discovery and Product Development, and prior to that as Senior VP, Global Head, Branded Product Development.
Dr. Leibovitch holds a Ph.D. in Physiology and pharmacology from Tel Aviv University and a Post-doc in Neurobiology from the Weizmann Institute of Science.
With an assembled group of passionate and aspiring individuals, Neswell Group is driving a new standard of therapeutics to the market. Advancing the groundwork of cannabinoid-based formulations through its pharmaceutical, biological and phytochemical advantages, our team is eager to bring growth to the wellness industry.